<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341701</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2018/37</org_study_id>
    <nct_id>NCT04341701</nct_id>
  </id_info>
  <brief_title>Phenotype Identification Based on Multimodal MRI Analysis of Patients With Bronchial Obstructive Diseases</brief_title>
  <acronym>PIMABOD</acronym>
  <official_title>Phenotype Identification Based on Multimodal MRI Analysis of Patients With Bronchial Obstructive Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that pulmonary and cardiac proton MRI allows phenotyping of patients with
      bronchial obstruction by cluster analysis based on quantitative multimodal imaging of
      bronchi, pulmonary vessels, pulmonary parenchyma, right and left ventricular function,
      myocardial fibrosis and pulmonary arterial pressure.

      Such imaging will also offer the advantage of being non-irradiating and without contrast
      products, which will ultimately allow CT to be replaced by MRI in the follow-up of bronchial
      obstructive patients, thus avoiding the risks associated with repeated exposure to ionizing
      radiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bronchial obstructive diseases such as asthma and chronic obstructive pulmonary disease
      (COPD) are very common and represent a major public health problem. The distinction between
      these two diseases is sometimes difficult. In each of these diseases, several clinical
      phenotypes or biological endotypes have been defined. For example, frequent exacerbating
      patients and / or hypereosinophilic patients are present in both diseases. In the severe
      states, cardiovascular comorbidities are the most frequent comorbidities and alter the
      prognosis.

      In these chronic obstructive patients, computed tomography (CT) allows a multimodal analysis
      of the bronchial wall, the lung parenchyma and pulmonary vessels. CT also allows a score
      analysis of coronary plaques. However, irradiation is significant and increases with repeated
      examinations. CT does not allow a comprehensive analysis of cardiac function, or an estimate
      of pulmonary artery pressure.

      Magnetic Resonance Imaging (MRI) is a proton non-ionizing alternative to CT, in particular
      when using 3D ultra-short echo-time (UTE) sequences. These 3D-UTE sequences decrease the
      effects of magnetic susceptibility and provide morphological and morphometric information on
      bronchi and lung comparable to those obtained by CT. Moreover, dedicated sequences add
      functional information on bronchi. Heart MRI allows more analyses, such as right and left
      ventricular systolic functions, an indirect estimate of pulmonary arterial pressure and the
      amount of diffuse myocardial fibrosis.

      Our project aims to identify morphological phenotypes through the pulmonary and heart MRI in
      patients with obstructive lung disease

      .
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 5, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>diagnostic imaging pilot study, exploratory, prospective, multi-center</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the number of the clusters</measure>
    <time_frame>Day 30</time_frame>
    <description>Number of the clusters will be defined using principal component analysis and dendrogram, based on the multimodal lung and heart MRI analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the Quality of the clusters</measure>
    <time_frame>Day 30</time_frame>
    <description>Quality of the clusters will be defined using Dunn index and non-hierarchical analysis based on the multimodal lung and heart MRI analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of age</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of sexe</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tobacco consumption</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of disease duration</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation score of SF-36 questionnaire</measure>
    <time_frame>Day 1</time_frame>
    <description>Determine the quality of life. SF36: 36-Item Short Form health survey Minimum = 0 and maximum = 100 Higher score means better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation with St Georges Quality of Life Questionnaire</measure>
    <time_frame>Day 30</time_frame>
    <description>Determine the quality of life. Minimum = 0 and maximum = 100 Higher score means worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of comorbidities</measure>
    <time_frame>Day 1</time_frame>
    <description>The presence of various comorbidities will be checked in a yes/No manner :
rhinitis
sinusitis
nasal polyposis
gastroesophageal reflux
obstructive sleep apnea
depression
anxiety
allery
heart failure (Left or Right)
hypertension
myocardial infarction
stroke
arteriopathy
arythmia
diabetis
dyslipidaemia
obesity
denutrition
osteoporosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine of Forced Expiratory Volume in one sec (FEV-1) during spirometry before and after bronchodilator</measure>
    <time_frame>day 1</time_frame>
    <description>Assessment of FEV-1/FVC during spirometry before and after bronchodilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine of Forced Vital Capacity (FVC) during spirometry before and after bronchodilator</measure>
    <time_frame>day 1</time_frame>
    <description>Assessment of FEV-1/FVC during spirometry before and after bronchodilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine of slow Vital Capacity (VC) during spirometry before and after bronchodilator</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine of Total Lung Capacity (TLC) during spirometry before and after bronchodilator</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine of Functional Residual Capacity (FRC) during spirometry before and after bronchodilator</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine of Residual Volume (RV) during spirometry before and after bronchodilator</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine of Carbon monoxide transfer capacity (TLCO)</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the value of blood heamoglobin</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the value of blood eosinophils</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the value of blood C-reactive protein</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the value of blood B-type natriuretic peptide</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the value of blood total IgE at</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the value of blood total IgE</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Asthma Copd</condition>
  <arm_group>
    <arm_group_label>COPD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>COPD according to GOLD 2019 but unrestricted to any level of bronchial reversibility established by the pulmonologist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>asthma according to GINA 2019 but without any smoking restriction</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>The procedure to study lung and heart MRI, performed on a 1.5T magnet (Siemens), without any injection or inhalation of contrast agent</description>
    <arm_group_label>Asthma</arm_group_label>
    <arm_group_label>COPD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman aged between 40 and 70 years.

          -  Having benefited under the current care of spirometry showing FEV / FVC
             pre-bronchodilation &lt;0.70 at steady state (i.e., without exacerbation from at least 4
             weeks).

          -  Having a diagnosis of asthma according to GINA 2019 without smoking restrictions or
             COPD according to GOLD 2019 but unrestricted to any level of bronchial reversibility
             to bronchodilator established by the pulmonologist.

          -  On stable cardiopulmonary medications for at least 4 weeks

          -  Having given his written informed consent.

        Exclusion Criteria:

          -  Subject deprived of liberty by judicial or administrative decision.

          -  Major protected by law.

          -  Subject not affiliated to a social security scheme, whether or not the beneficiary of
             such a regime.

          -  Pregnant or breastfeeding women

          -  Inability to complete the Questionnaire SF-36 and SGQLQ.

          -  Subject in times of exclusion in relation to another protocol.

          -  History of pulmonary fibrosis, primary pulmonary hypertension and cystic fibrosis.

          -  History of lung resection (referred to oncological or volume reduction)

          -  History of cancer except skin cancer (squamous and Basal) under 5 years

          -  History of chest radiation

          -  Pacemaker carrier subject or implantable defibrillator, intraocular metallic foreign
             body, metal clip intracranial, heart valve prosthesis kind Starr-Edwards pre-6000, or
             biomedical insulin pump type device, Neurostimulator or cochlear implant, Metal
             patches.

          -  Subject claustrophobic or unable to stay elongate during 30 minutes.

          -  Subject with a waist circumference greater than 200 cm.

          -  Occurrence of an exacerbation between the FE and MRI

          -  Uninterpretable MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick BERGER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick BERGER, MD, PhD</last_name>
    <phone>+335 57 65 65 13</phone>
    <email>patrick.berger@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Virginie NIEL</last_name>
    <phone>+335 57 62 31 94</phone>
    <email>virginie.niel@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre hospitalier de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Elise ABRAHAM, MD</last_name>
      <phone>+335 59 44 35 35</phone>
      <email>eabraham@ch-cotebasque.fr</email>
    </contact>
    <investigator>
      <last_name>Elise ABRAHAM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Augustin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Annaig OZIER, MD</last_name>
      <phone>+335 56 24 21 79</phone>
      <email>ozierannaig@icloud.com</email>
    </contact>
    <investigator>
      <last_name>Annaig OZIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Médical Toki Eder</name>
      <address>
        <city>Cambo-les-Bains</city>
        <zip>64250</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alain BERNADY, MD</last_name>
      <phone>+335 59 93 56 00</phone>
      <email>al.bernady@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alain BERNADY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Le Cluzeau - CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Boris MELONI, MD</last_name>
      <phone>+335 55 05 68 81</phone>
      <email>boris.melloni@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Boris MELONI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Pneumologie Bordeaux Rive droite</name>
      <address>
        <city>Lormont</city>
        <zip>33310</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent FALQUE, MD</last_name>
      <phone>+335 56 32 80 58</phone>
      <email>laurent.falque@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent FALQUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévêque - CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrick BERGER, MD, PhD</last_name>
      <phone>+335 57 65 65 13</phone>
      <email>patrick.berger@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Virginie NIEL</last_name>
      <phone>+335 57 62 31 94</phone>
      <email>virginie.niel@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre-Olivier GIRODET, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick BERGER, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maéva ZYSMAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>multimodal</keyword>
  <keyword>phenotypes</keyword>
  <keyword>lung</keyword>
  <keyword>heart</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

